This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Dentistry/ Oral Medicine  • Dermatology  • Dermatologic Disorders  • Randomized Controlled Trial  • Dermatologic Disorders, Other  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Martin H. Thornhill, MBBS, PhD; Lorena Baccaglini, DDS, PhD; Elizabeth Theaker, BDS, MPhil; Michael N. Pemberton, MBBS

Arch Dermatol. 2007;143(4):463-470.

Objective  To evaluate pentoxifylline for the treatment of recurrent aphthous stomatitis.

Design  A 60-day, randomized, double-blind, placebo-controlled trial with a 60-day no treatment follow-up.

Setting  An oral medicine specialist referral center in Manchester.

Participants  Forty-nine volunteers who passed the initial assessment for recurrent aphthous stomatitis entered a pretrial phase in which their eligibility for the trial phase of the study was assessed. Sixteen subjects were deemed ineligible, and 7 failed to attend or withdrew. The remaining 26 subjects were randomized to placebo or treatment. Six subjects withdrew because of adverse effects, and 1 was unavailable for follow-up.

Intervention  Pentoxifylline (also called oxpentifylline), 400 mg 3 times daily, or matching placebo.

Main Outcome Measure  A reduction in the median pain score, ulcer size, number of ulcers, or total number of ulcer episodes.

Results  Patients taking pentoxifylline had less pain and reported smaller and fewer ulcers compared with baseline. Patients taking placebo reported no improvement in these variables. Patients taking pentoxifylline also reported more ulcer-free days than those taking placebo. However, the differences were small and, with the exception of median ulcer size (P = .05), did not reach statistical significance. Adverse effects were common with pentoxifylline, but not significantly different from those experienced by patients taking placebo.

Conclusions  Although pentoxifylline may have some benefit in the treatment of recurrent aphthous stomatitis, the benefit is limited. It may have a role in the treatment of patients unresponsive to other treatments, but cannot yet be recommended as a first-line treatment.

Trial Registration  clinicaltrials.gov Identifier: NCT00315679

Author Affiliations: Department of Oral and Maxillofacial Medicine and Surgery, The University of Sheffield School of Clinical Dentistry, Sheffield (Dr Thornhill), and University Dental Hospital of Manchester, Manchester (Ms Theaker and Dr Pemberton), England; and Department of Community Dentistry and Behavioral Science, University of Florida College of Dentistry, Gainesville (Dr Baccaglini).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Treatment of Oral Erosive Lichen Planus With 1% Pimecrolimus Cream: A Double-blind, Randomized, Prospective Trial With Measurement of Pimecrolimus Levels in the Blood
Thierry Passeron, Jean-Philippe Lacour, Eric Fontas, and Jean-Paul Ortonne
Arch Dermatol. 2007;143(4):472-476.
ABSTRACT | FULL TEXT  

Oral Lichen Planus: A Case Series With Emphasis on Therapy
Dorothea C. Torti, Joseph L. Jorizzo, and Martha Ann McCarty
Arch Dermatol. 2007;143(4):511-515.
ABSTRACT | FULL TEXT  

New and Old Therapeutics for Oral Ulcerations
Alison Bruce and Roy S. Rogers, III
Arch Dermatol. 2007;143(4):519-523.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A NEW LOOK AT THE XANTHINE ALKALOIDS
Scheindlin
Mol. Interv. 2007;7:236-242.
FULL TEXT  

New and Old Therapeutics for Oral Ulcerations
Bruce and Rogers
Arch Dermatol 2007;143:519-523.
FULL TEXT